한글목차

세계의 티로신 키나아제 저해제 시장은 2024년 520억 7,000만 달러에서 2030년까지 830억 9,000만 달러로, CAGR 8.10%로 성장할 것으로 예측됩니다. 티로신키나아제 억제제(TKI)는 세포 신호전달, 성장, 분열에 필수적인 효소인 티로신키나아제의 작용을 선택적으로 억제하여 종양의 증식을 억제하도록 설계된 의약품의 일종입니다. 이러한 표적 치료제 세계 시장은 주로 전 세계에서 증가하는 암 유병률에 의해 주도되고 있으며, 첨단이고 효과적인 치료법에 대한 수요가 증가하고 있습니다.

주요 시장 성장 촉진요인

세계에서 증가하는 암 발병률은 티로신 키나아제 억제제 시장의 주요 촉진요인으로 작용하고 있습니다. 전 세계에서 새롭게 진단되는 암 환자의 수가 증가함에 따라 혁신적이고 효과적인 치료 전략에 대한 수요는 필연적으로 증가하고 있습니다.

주요 시장 과제

세계 티로신 키나아제 억제제 시장의 성장을 저해하는 가장 큰 문제는 이러한 첨단 치료제에 따른 막대한 비용입니다. 높은 치료비는 특히 의료 시스템이 엄격한 예산 제약 하에서 운영되고 공공 상환 정책이 엄격한 지역에서 환자의 접근을 직접적으로 제한하고 있습니다.

주요 시장 동향

TKI 병용요법 증가는 치료 패러다임의 중요한 전환점으로, 치료 효과의 향상과 암의 복잡한 내성 기전에 대한 대응을 실현하고 있습니다. 이러한 추세는 티로신 키나아제 억제제를 화학요법이나 면역요법 등 다른 약물과 병용하여 우수한 환자 결과를 달성하는 것을 포함합니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 유형별(BCR-ABL 티로신 키나아제 저해제, 상피 성장인자 수용체(EGFR) 티로신 키나아제 저해제, 혈관 내피 성장인자 수용체(VEGFR) 티로신 키나아제 저해제, 기타)
  • 용도별(만성 골수성 백혈병(CML), 폐암, 유방암, 신세포암, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 티로신 키나아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 티로신 키나아제 저해제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

제16장 전략적 제안

제17장 조사회사 소개·면책사항

영문목차

The Global Tyrosine Kinase Inhibitors Market will grow from USD 52.07 Billion in 2024 to USD 83.09 Billion by 2030 at a 8.10% CAGR. Tyrosine Kinase Inhibitors, or TKIs, are a class of pharmaceutical drugs designed to selectively block the action of tyrosine kinases, enzymes crucial for cell signaling, growth, and division, thereby inhibiting tumor proliferation. The global market for these targeted therapies is primarily driven by the escalating prevalence of cancer worldwide, which necessitates advanced and effective treatment modalities.

Key Market Drivers

The escalating global cancer incidence represents a primary impetus for the Tyrosine Kinase Inhibitors market. The sheer volume of new cancer diagnoses worldwide inherently drives the demand for innovative and effective therapeutic strategies. As the global population ages and lifestyles evolve, the burden of cancer continues to grow, necessitating targeted treatments that offer improved efficacy and patient outcomes.

Key Market Challenges

A significant challenge impeding the growth of the Global Tyrosine Kinase Inhibitors Market is the substantial cost associated with these advanced therapies. High treatment expenses directly restrict patient access, particularly in regions where healthcare systems operate under tight budgetary constraints and public reimbursement policies are stringent. This financial barrier limits the number of patients who can initiate and sustain TKI treatments, irrespective of medical need. Consequently, reduced patient uptake translates into lower sales volumes and slower market penetration for manufacturers of these inhibitors.

Key Market Trends

The increasing adoption of TKI combination therapies represents a pivotal shift in treatment paradigms, enhancing therapeutic efficacy and addressing complex resistance mechanisms in cancer. This trend involves combining tyrosine kinase inhibitors with other agents, such as chemotherapy or immunotherapies, to achieve superior patient outcomes.

Key Market Players

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

Report Scope:

In this report, the Global Tyrosine Kinase Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tyrosine Kinase Inhibitors Market, By Type:

• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Other

Tyrosine Kinase Inhibitors Market, By Application:

• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other

Tyrosine Kinase Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tyrosine Kinase Inhibitors Market.

Available Customizations:

Global Tyrosine Kinase Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tyrosine Kinase Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other)
  • 5.2.2. By Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Tyrosine Kinase Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Tyrosine Kinase Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Tyrosine Kinase Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Tyrosine Kinase Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Tyrosine Kinase Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tyrosine Kinase Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bayer AG
• 15.3. Boehringer Ingelheim International
• 15.4. Bristol-Myers Squibb Company
• 15.5. Eisai Co. Ltd
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Johnson and Johnson
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer